| Biogen Inc. | 232.08 / -0.47% |
| Date/Time | 08/22 / 21:59 |
| Chg. / Chg.(%) | -1.10 / -0.47% |
| Bid | 232.07 / 1 |
| Ask | 232.39 / 1 |
| Open | 232.77 |
| Previous Close | 233.18 |
| High | 233.54 |
| Low | 229.74 |
| Volume [USD] | 5,396,566.09 |
| Volume [Units] | 38,377 |
| Price fixings | 231 |
| ISIN | US09062X1037 |
| Security | BIIB |
| Exchange | Cboe US |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| TradeGate | 211.050 |  |
48 |
| Vienna Globa.. | 210.39 |  |
0 |
| München | 209.40 | |
0 |
| Hamburg | 209.40 | |
0 |
| Düsseldorf | 209.30 | |
0 |
| Berlin | 210.35 | |
0 |
| Frankfurt | 209.3500 | |
0 |
| Hannover | 209.40 | |
0 |
| Lang & Schwa.. | 209.400 | |
|
| gettex | 209.800 | |
|
| Stuttgart | 209.250 | |
|
| NASDAQ | 232.0600 | |
732,929 |
| Cboe US | 232.08 | |
38,377 |
| IEX | 232.03 | |
28,205 |
| London Inter.. | 231.95 | 445 | |
| Mexico | 4,440.20 |  |
5 |
| Xetra | 208.80 | 0 | |
| SIX Swiss Ex.. | 232.00 |
News
- Global Personalized Medicine (PM) Market Anticipated to Near $3.2 Trillion by 2025 - PM Therapeutics is Projected to Register the Fastest CAGR
08/21/2019 / 14:09 - GlobeNewswire - Biogen and Invitae Announce Availability of Rapid Results in Genetic Testing Program for Spinal Muscular Atrophy (SMA) to Improve Speed of Diagnosis for Patients
08/20/2019 / 13:30 - GlobeNewswire - Neurologic Disorders Therapeutics: Global Market Analysis Through 2019-2023 with Biogen, Roche, Johnson & Johnson Services, Novartis, and Pfizer Leading
08/19/2019 / 10:05 - GlobeNewswire - Global Hemophilia Market Outlook 2019-2024: Focus on Recombinant, Immune Tolerance Induction (ITI), and Gene Therapies
08/01/2019 / 15:41 - GlobeNewswire - Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
07/30/2019 / 13:30 - GlobeNewswire
Real-time